新西兰注册研究:开放与机器人根治性前列腺切除术后的患者报告结局
该研究基于新西兰前列腺癌结局注册库(PCOR-NZ),比较2016年1月至2024年12月间接受开放根治性前列腺切除术(ORP)或机器人辅助腹腔镜前列腺切除术(RALP)作为初始治疗的前列腺癌患者的EPIC-26患者报告结局。共4889名男性完成问卷,其中ORP 2844例(58.1%),RALP 2045例(41.8%)。结果显示RALP组在所有EPIC-26领域均有更高的治疗后评分,其中尿失禁和性功能领域的调整平均差异超过最小临床重要差异阈值,且RALP组每日零垫使用率更高、每日≥2垫使用率更低。
要点
- RALP组在尿失禁和性功能领域的调整平均差异超过最小临床重要差异阈值。
- RALP组12个月时每日零垫使用率65.1% vs 54.4%,每日≥2垫使用率3.9% vs 10.0%。
- RALP组报告性功能“好”至“非常好”的比例更高(13.7% vs 5.3%)。
核心结论
- RALP与所有EPIC-26领域更高的患者报告结局相关,并在性功能、尿失禁和减少尿垫使用方面具有临床意义的获益。
研究设计与样本
- 基于新西兰前列腺癌结局注册库(PCOR-NZ)的分析,纳入2016年1月至2024年12月接受ORP或RALP作为初始治疗且完成基线或术后12个月EPIC-26问卷的男性。
- 共4889名男性完成问卷,ORP组2844例(58.1%),RALP组2045例(41.8%);基线问卷完成率52.3%,治疗后12个月完成率78.8%。
- 采用多变量分析调整年龄、前列腺特异性抗原和国际泌尿病理学会分级,计算平均差异。
主要发现
- RALP组在所有EPIC-26领域均有更高的治疗后评分。
- 尿失禁领域调整平均差异6.9分(95%CI 4.6-9.2,P<0.001),性功能领域调整平均差异11.4分(95%CI 9.1-13.7,P<0.001),均超过最小临床重要差异阈值。
- 排尿梗阻、肠道和激素领域未达到临床显著性。
- 12个月时RALP组每日零垫使用率更高(65.1% vs 54.4%,P<0.001),每日≥2垫使用率更低(3.9% vs 10.0%,P<0.001)。
- RALP组报告性功能“好”至“非常好”的比例更高(13.7% vs 5.3%,P<0.001)。
关键数值与推荐
- EPIC-26评分范围0-100分(100为最佳)。
- 最小临床重要差异阈值:尿失禁6-9分,排尿梗阻5-7分,肠道4-6分,性功能10-12分,激素4-6分。
临床怎么用
- 对于选择根治性前列腺切除术的前列腺癌患者,RALP在12个月时可能带来更好的尿失禁和性功能患者报告结局。
- 临床咨询时可参考RALP与ORP在尿垫使用和性功能方面的差异,辅助术式选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Our objective was to compare functional outcomes between open radical prostatectomy (ORP) and robotic-assisted laparoscopic prostatectomy (RALP) in New Zealand. METHODS: We analysed responses from men in the Prostate Cancer Outcome Registry of New Zealand (PCOR-NZ) who underwent ORP or RALP as primary treatment for prostate cancer between January 2016 and December 2024. We included men who completed an Expanded Prostate Cancer Index - 26 (EPIC-26) patient-reported outcome measure (PROM) questionnaire either at baseline, 12 months after radical prostatectomy or both. EPIC-26 scores range from 0 to 100 (100 = best score). Established thresholds assessed minimal clinically important differences; urinary incontinence (6-9 points), urinary obstruction (5-7 points), bowel (4-6 points), sexual (10-12 points) and hormonal (4-6 points). Mean differences were calculated using multivariate analysis to adjust for age, prostate-specific antigen and International Society of Urological Pathology grade. Additional analyses assessed daily pad usage and patient-reported sexual function. RESULTS: Of the 4889 men who completed a questionnaire, 2844 (58.1%) underwent ORP and 2045 (41.8%) underwent RALP. PROM completion rates were 52.3% at baseline and 78.8% at 12 months after treatment. Patients who underwent RALP had higher post-treatment PROM scores in all domains. Adjusted mean differences for urinary incontinence (6.9 points, 95% confidence interval 4.6-9.2 P < 0.001) and sexual (11.4 points, 95% confidence interval 9.1-13.7, P < 0.001) domains were above the threshold for minimal clinically important difference. Urinary obstruction, bowel and hormonal domains did not reach clinical significance. At 12 months, RALP had a higher rate of zero pads/day usage (65.1% vs 54.4% P < 0.001) and lower two or more pads/day usage (3.9% vs 10.0% P < 0.001). More men in the RALP group reported a 'good' to 'very good' sexual function at 12 months (13.7% vs 5.3%, P < 0.001). CONCLUSION: RALP is associated with higher PROMs across all EPIC-26 domains, with clinically meaningful benefit in sexual function, urinary incontinence and reduced incontinence pad usage at 12 months.
引用
- Long K, Hutchinson J, Acland G, et al. Patient-reported outcomes after open and robotic radical prostatectomy: a New Zealand registry study. BJU Int. 2026. PMID: 42764237. doi:10.1111/bju.70459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。